Ixazomib for Desensitization (IXADES) in Highly Sensitized Kidney Transplant Candidates: A Phase II Clinical Trial.

In conclusion, treatment with ixazomib/dexamethasone engendered mild to moderate toxicity. The impact on anti-HLA was modest and in the case of anti-HLA-DR paradoxical. Clinical trials combining ixazomib with other immunosuppressive agents may be more effective in addressing antibody-mediated processes in kidney transplantation.